Introduction
NBAS-associated disease is a rare autosomal recessive disorder with a broad spectrum of clinical symptoms, mainly involving liver, growth, skeletal system, nervous system, integument, immune system, and musculature. Biallelic pathogenic
NBAS variants were first described in an isolated Russian population in 2010 causing a syndrome comprising short stature, optic atrophy, and Pelger-Huët anomaly (SOPH syndrome; MIM 614800) [
1]. In 2015,
NBAS variants were linked to fever-related recurrent acute liver failure [infantile liver failure syndrome 2 (ILFS2), MIM 616483] [
2]. To date, NBAS-associated disease has been documented in at least 110 patients from 97 families and
NBAS variants can be classified into three subgroups according to the affected part of the protein: “Sec39,” with a predominant hepatic phenotype (ILFS2), “C-terminal” with the multisystemic SOPH phenotype, and “β-propeller” with a combined phenotype (ILFS2-SOPH) [
3].
Immunological symptoms and laboratory alterations such as frequent infections, hypogammaglobulinemia, low natural killer (NK) cell numbers, and neutropenia have been observed in more than 60% of patients with NBAS-associated disease throughout all defined subgroups [
3]. However, a detailed description of abnormal immunological parameters has only been published in one patient presenting with predominant hypogammaglobulinemia who was detected by abnormal “κ-deleting recombination excision circles” (KREC) via newborn screening [
4], suggesting NBAS-associated disease to be an inborn error of immunity. A systematic analysis of a characteristic immunophenotype or altered immunological functionality in NBAS-associated disease has remained elusive.
Inborn errors of immunity can present with isolated immune cell dysfunction, but can also be part of a multisystemic presentation as in DiGeorge syndrome [
5], ataxia teleangiectasia [
6,
7], or in some forms of familial hemophagocytic lymphohistiocytosis (FHL) [
8]. Especially with onset in early infancy, they can be life-threatening, emphasizing the need for early disease recognition, clinical awareness, and high throughput genetic testing [
9], but also mechanistic understanding to improve patient management and care [
10].
In this study, we systematically determine key immunological parameters in fifteen individuals with confirmed NBAS-associated disease including the cellular composition and function of leukocytes in peripheral blood, immunoglobulin levels, and cytokine gene expression. We reveal that NBAS-associated disease displays a common immunological signature of impaired humoral adaptive immunity and a defective NK cell compartment and, therefore, should be considered an inborn error of immunity.
Patients and Methods
Patient Recruitment, Controls, and Data Acquisition
Fifteen patients with biallelic pathogenic variants in NBAS from all three subgroups (ILFS2, SOPH, ILFS2-SOPH) were included in this prospective observational study. All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013. Informed consent to participate in the study was obtained from all patients or from their parents in the case of minor patients. The study was approved by the ethical committee of the University Hospital Heidelberg and local ethical committees.
The general clinical parameters included country of origin, sex, and age at onset of clinical symptoms. For clinical phenotyping, human phenotype ontology terms were used (see
Supplemental Material). For immunological phenotyping, blood from all individuals was drawn outside episodes of inflammation. If more than one measurement per patient was performed, the arithmetic mean was calculated. For flow cytometry and gene expression analysis, gender-matched and age-matched healthy donors were included. For NK cell degranulation assays additional blood samples from six patients were obtained and gender-matched healthy donors were recruited. Both recruitments took place at the University Hospital Heidelberg. Database was closed on December 1, 2019.
Gene Expression Analysis
Heparinized whole blood of 0.5 ml was incubated with 0.1 ml RPMI1640 or stimulated in RPMI1640 with 100 ng/ml PMA and 5 μg/ml ionomycin (Sigma) for 3 h at 37 °C and 5% CO2. Red cells were lysed twice with ACK buffer. Afterward, the leukocytes were lysed with 400 μl of MagNA-Pure lysis buffer (Roche) containing 1% DTT (Roche, cat. no. 10708 984001), and the samples were frozen at − 70 °C. After thawing, the lysates were thoroughly mixed and transferred into the MagNA-Pure sample cartridge and total RNA was isolated with the MagNA-Pure-LC device using the RNA standard protocol for cells. The elution volume was set to 50 μl. An aliquot of 8.2 μl mRNA was reversely transcribed using AMV-RT and oligo-(dT) as primers (First Strand cDNA synthesis kit, Roche) in a thermocycler according to the manufacture’s protocol. After termination of the cDNA synthesis, the reaction mixture was diluted to a final volume of 500 μl and stored at − 20 °C until PCR analysis.
Primer sets optimized for the LightCycler® (RAS) were developed and purchased from SEARCH-LC GmbH (
www.Search-LC.com). The PCR was performed with the LightCycler® FastStart DNA Sybr Green kit (RAS) according to the protocol provided in the parameter-specific kits. To control for specificity of the amplification products, a melting curve analysis was performed. The copy number was calculated from a standard curve, obtained by plotting known input concentrations of four different plasmids at log dilutions to the PCR-cycle number (CP) at which the detected fluorescence intensity reaches a fixed value.
To correct for differences in the content of mRNA, the calculated transcript numbers were normalized according to the expression of the housekeeping gene peptidylprolyl isomerase B (PPIB). Values were thus given as transcripts per 1,000 transcripts of PPIB.
Cytokine Measurement
Cytokine measurement was performed by Myriad RBM (TX, USA) as follows: Using automated pipetting, an aliquot of each sample was added to individual microsphere multiplexes of the selected multi-analyte profile (MAP) and blocker. This mixture was thoroughly mixed and incubated at room temperature for 1 h. Multiplexed cocktails of biotinylated reporter antibodies were added robotically and after thorough mixing, incubated for an additional hour at room temperature. Multiplexes were labeled using an excess of streptavidin–phycoerythrin solution, thoroughly mixed, and incubated for 1 h at room temperature. The volume of each multiplexed reaction was reduced by vacuum filtration and washed 3 times. After the final wash, the volume was increased by addition of buffer for analysis using a Luminex instrument, and the resulting data was interpreted using proprietary software developed by Myriad RBM. For each multiplex, both calibrators and controls were included on each microtiter plate. Eight-point calibrators to form a standard curve were run in the first and last column of each plate and controls at 3 concentration levels were run in duplicate. Study sample values for each of the analytes were determined using 4 and 5 parameter logistics, with weighted and non-weighted curve fitting algorithms included in the data analysis package.
PBMC Isolation and Culture
Peripheral blood mononuclear cells (PBMCs) were isolated from unfractionated peripheral blood by Ficoll-Hypaque density gradient (density 1.077 g/ml, Biochrom, VWR) centrifugation. For functional and phenotypic analyses, PBMCs were resuspended in SCGM medium (CellGenix) containing 10% human serum (pooled human AB serum, # P041702, Pan-Biotech) and cultured for 2 days without or with 400 U/ml of IL-2 (kindly provided by the NIH, USA).
Degranulation
CD107a upregulation on NK cells of NBAS-deficient patients or healthy controls was measured after co-culture of NK cells without or with the erythroleukemic cell line K562 (ATCC) at 1:1 ratio (each 5 × 104 cells) in duplicate for 4 h in the presence of anti-CD107a FITC (clone A4A3, Biolegend) or anti-CD107a PE (clone A4A3, Biolegend, and GolgiPlug, 1/100 v/v, BD Bioscience) in 96-well plates in RPMI 1640 (Invitrogen) supplemented with heat-inactivated 10% FCS (Invitrogen) and 1% penicillin/streptomycin (Sigma-Aldrich).
Flow Cytometry
The immunophenotyping was performed in whole blood. Absolute cell count was measured using the BDMultitest™ 6-color TBNK reagent with BD Trucount™tubes (BD Biosciences, Heidelberg, Germany). The panels are modified recommendations of the “Human Immunophenotyping consortium” [
11]. Briefly, Panel-1 consisted of 17 antibodies to characterize the major T cell populations, including naïve and various memory/effector populations (CD2; CD3; CD4; CD8; TCR ƴδ; CD45RA; CD197 (CCR7); CD28; CD57 and CD127). Th1, Th2; Th17, and Tfh cells were identified with the following antibodies: CD183 (CXCR3); CD185 (CXCR5); and CD196 (CCR6). Activation was monitored with antibodies against HLA-DR, CD38, CD278 (ICOS), and CD279 (PD1). Using CD3 as a backbone for absolute quantification, with this comprehensive panel more than 200 defined subpopulations have been quantified in absolute numbers as well as in various ratios. Panel-2 consists of 8 parameters (CD3; CD19; CD20; anti-IgD; CD27; CD10; CD24; and CD38), allowing the identification of transitional, naïve, and memory B cells as well as circulating plasmablasts both in absolute numbers (CD19 backbone) and in various ratios. Panel-3 identified various NK, monocyte and DC subsets and included antibodies with the following specificities: CD11c; CD123; CD14; CD16; CD19; CD2; CD20; CD25; CD3; CD45; CD56; CD57; CD8a; HLA-DR; and M-DC8. Using NK cells as backbone, absolute numbers were calculated for 50 different populations. Finally, the Treg subset was characterized using the following antibodies: CD127; CD194 (CCR4); CD25; CD3; CD4; CD45; CD45RO; and anti-HLA-DR. CD4 + T-lymphocytes served as backbone for the absolute quantification of the different subsets. The analysis was performed on an LSR Fortessa Analyzer (Special Order Research Product) (BD Biosciences). The detailed setup, staining, gating, and analysis procedures have been recently described [
12]. Cell surface expression of CD107a and CD69 (marker for NK cell activation) and intracellular expression of perforin and granzyme B of CD3
− CD56
+ NK cells in PBMCs was measured by flow cytometry (LSR Fortessa II, BD Bioscience) and analyzed with FlowJo 10 software (FlowJo LLC). Intracellular staining was performed using the “Cytofix/Cytoperm” kit (BD Bioscience). (For information on antibodies, see
Supplemental Material.)
Statistics
Statistical analyses were performed with GraphPad Prism. Mean values of two groups were compared by Mann–Whitney U-tests. Mean values of multiple groups were assessed by one-way ANOVA followed by multiple comparisons post hoc tests as indicated. Error bars represent the SEM and asterisks indicate the significance levels (*P < 0.05; **P < 0.01; ***P < 0.001). The correlation coefficient R2 was calculated by linear regression.
Discussion
NBAS-associated disease is a complex disorder with a heterogeneous clinical spectrum involving multiple organ systems that can be categorized into three different clinical subgroups “β-propeller,” “Sec39,” and “C-terminal” [
3]. Abnormalities of the immune system are present in a majority of NBAS-deficient individuals of all three subgroups [
3], but no detailed characterization of this affection has been done so far. In this study, we demonstrate that the immunodeficiency phenotype of NBAS-associated disease is characterized by quantitative and qualitative NK cell and B cell deficiency. The lower NK cell counts correlated with the loss of the more mature CD56dim CD16
+ cytotoxic NK cell subset, pointing toward dysfunctional NK cell maturation and/or disrupted mature NK cell homeostasis. The residual NK cell population exerted a significantly lower potential for activation and degranulation upon contact with K562 target cells. This hyporesponsive state could be rescued in vitro by pre-activation with the NK cell-stimulating cytokine IL-2. Due to a lack of available biosamples, functional analysis of NK cells was tested in patients from the “β-propeller” and the “Sec39” subgroup, but not in patients from the “C-terminal” group.
Altered NK cell development and numbers of NK cells and ensuing susceptibility to herpes or papilloma virus infections are hallmarks of classical NK cell deficiencies [
15]. Importantly, patients with NBAS-associated disease suffer from frequent and recurrent infections (Table
2 and authors’ unpublished data) such as human herpesvirus 6-associated severe crisis of NK cell depletion and liver failure in individual NBAS 60. In addition, susceptibility of NBAS-deficient patients to viral infections may also be facilitated by defective humoral immunity, since consistently low IgG serum levels and partially impaired specific antibody generation after vaccination were prevalent in these patients [
3].
Among classical NK cell deficiencies, the most frequently cited defect, GATA2 deficiency, affects CD56
bright NK cells [
16], while NK cell deficiencies due to variants in
IRF8 and
MCM4 mainly affect CD56
dim NK cells and present with impaired cytolytic function, similar to the pattern observed in our patients [
17,
18].
Dysfunctional NK cell degranulation is one of the diagnostic parameters of hemophagocytic lymphohistiocytosis (HLH) which is a life-threatening hyperinflammatory syndrome. HLH has been categorized into primary FHL, syndromic HLH, and secondary HLH mainly driven by infections. Primary HLH itself is characterized by uncontrolled activation of lymphocytes and macrophages due to impaired cytotoxic function of NK cells and T cells, leading to excessive cytokine production like IFN-γ [
19]. While the cytotoxic potential of NK cells in NBAS-deficient patients from the “β-propeller” and “Sec39” subgroup was likewise reduced, we did not observe increased pro-inflammatory cytokine levels in serum of NBAS-deficient patients in remission. However, no data on cytokine levels or the status of myeloid cell activation during inflammatory states or, of specific interest, during episodes of liver failure were available.
Systemic hyperinflammation in the context of HLH is a major cause of acute liver failure in the first year of life [
20,
21]. However, there is growing evidence that dysregulated hepatic inflammation per se can lead to acute liver failure [
22,
23] and NBAS-deficient patients from the “β-propeller” and “Sec39” subgroup have fever-related acute liver failure [
3]. As elevated temperature was shown to cause a reduction in NBAS protein level and cell viability [
24], fever might affect NK cell homeostasis and viability particularly in NBAS-deficient cells. In line with this is the observation that absolute NK cell numbers further decreased in individuals NBAS 8 and NBAS 60 under the level of detection during febrile episodes (data not shown). However, NK cells were low in number and dysfunctional also outside episodes of inflammation or hepatic dysfunction. There may be evolution of the immune phenotype in NBAS-associated over life time, which could be one explanation for the immune-phenotypic inconsistency among siblings sharing the same genotype (NBAS 60, NBAS 88). Further studies are needed to study NK cell activation, cell signaling of the JAK-STAT pathways [
23], cytokine secretion, such as IL-18, and IL-18BP [
22], and degranulation in NBAS deficiency especially during fever-triggered acute liver failure. This might set the stage of targeted treatment of NBAS deficiency associate acute liver failure, e.g., with Janus kinase inhibitors [
25] or IL-18 binding protein (ClinicalTrials.gov Identifier: NCT03113760).
Apart from a hepatic phenotype, the FHL, and syndromic HLH can include growth retardation, neurological dysfunction [
26‐
28] and hypogammaglobulinemia (FHL5 [
29], Griscelli syndrome type 2 [
20,
30], XLP-1 deficiency, and XPL-2/XIAP deficiency [
31]), all of which are prevalent in NBAS deficiency [
3]. Thus, HLH and NBAS-associated disease share clinical symptoms and immunological abnormalities (Table
3).
Table 3
FHL and HLH syndromes: genes, functions, and cytometric abnormalities
FHL | FHL1 | 267700 | Unknown | Unknown | Not available |
FHL2 | 603553 | PRF1 | Pore formation | Decreased / absent perforin expression |
FHL3 | 608898 | UNC13D | Vesicle priming | Decreased CD107a expression |
FHL4 | 603552 | STX11 | Vesicle fusion | Decreased CD107a expression |
FHL5 | 601717 | STXBP2 | Vesicle fusion | Decreased CD107a expression |
HLH syndromes | Griscelli syndrome type 2 | 607624 | RAB27A | Vesicle docking | Decreased CD107a expression |
Chediak-Higashi syndrome | 214500 | LYST | Vesicle trafficking | Decreased CD107a expression |
Hermansky-Pudlak syndrome 2 | 608233 | AP3B1 | Vesicle trafficking | Decreased CD107a expression |
Hermansky-Pudlak syndrome 9 | 614171 | BLOC1S6 | Vesicle trafficking | Decreased CD107a expression |
| NBAS-associated disease (ILFS2, SOPH) | 616483; 614800 | NBAS | Vesicle trafficking | Decreased CD107a expression |
FHL2-5 and syndromic HLH share a pathophysiology of defective biogenesis and trafficking of cytolytic vesicles including their priming and fusion with the plasma membrane (Table
3 [
8]). The Sec39 domain of NBAS is part of the syntaxin 18 (STX18) complex, a soluble
N-ethylmaleimide-sensitive-factor attachment receptor (SNARE) complex involved in anterograde and retrograde transport between endoplasmic reticulum and Golgi [
2,
24,
32,
33]. Additionally, STX18 has been shown to directly interact with syntaxin 4 (STX4), a known mediator of degranulation of cytolytic vesicles that is located at the plasma membrane [
34,
35]. While degranulation activity of NK cells is decreased in NBAS-deficient patients, expression levels of granzyme B and perforin remain widely unchanged. We speculate that impaired STX18 complex function in NBAS-associated disease might impair NK cell cytotoxicity by disturbing granule release of cytotoxic vesicles. More globally and since STX4 is known to be involved in IgG exocytosis, insulin secretion and glucose uptake in the musculature and adipose tissue, a dysfunctional interaction between STX4 and STX18 might be a driver not only for hypogammaglobulinemia but also for diabetes mellitus type 1, muscular hypotonia, and reduced subcutaneous fat tissue, which are all found in NBAS-associated disease [
36]. Other diseases affecting STX18 complex function such as RINT1 deficiency, which is associated with recurrent liver failure and skeletal abnormalities and hence shows phenotypic overlap to NBAS deficiency, should be investigated for trafficking of cytolytic vesicles and impaired NK cell cytotoxicity [
37].
We show that NK cell activation and degranulation were improved by pre-activation of NK cells with IL-2 in vitro in patients from the “β-propeller” and “Sec39” subgroup, suggesting that IL-2 might enhance NBAS expression and/or function or promote alternative molecular pathways mediating cytolytic vesicle release in those. Similarly, NK cell degranulation was shown to be improved after 48–72-h IL-2 stimulation in NK cells of FHL4 patients due to variants in
STX11 and FHL5 due to variants in
STXBP2, with both genes coding for SNARE proteins [
29,
38]. Hence, cytokine therapy with clinically approved IL-2 or IL-15 formulations [
36,
39,
40] might support NK cell function in NBAS-deficient patients. Clearly, future in-depth mechanistic studies are warranted to better understand the complex pathophysiology of NBAS deficiency.
In conclusion, NBAS variants cause a multisystem disease including an immunodeficiency phenotype marked by low NK cell numbers and NK cell dysfunction as well as reduction of naïve B cells and serum immunoglobulin levels. Patients with pathogenic NBAS variants should be investigated accordingly.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.